JOHN LATERRA, M.D.
Neurology at Wolfe St, Baltimore, MD
License number
Maryland D37018
Category
Neurology
Type
Neurology
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-9441
Personal information
See more information about JOHN LATERRA at radaris.comName
Address
Phone
5401 Saint Albans Way, Baltimore, MD 21212
5401 Saint Albans Way, Baltimore, MD 21212
102 Brookebury Dr, Reisterstown, MD 21136
Organization information
See more information about JOHN LATERRA at bizstanding.comJohn Laterra MD
600 N Wolfe St, Baltimore, MD 21287
Industry:
Neurologist
Phone:
(410) 955-9441 (Phone)
John Joseph Laterra
Professional information
See more information about JOHN LATERRA at trustoria.com
Dr. John Laterra, Baltimore MD - MD (Doctor of Medicine)
Dr. John Laterra, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
Johns Hopkins Hospital Neurolgy
1800 Orleans St SUITE 119, Baltimore 21287
(410) 614-3853 (Phone)
1800 Orleans St SUITE 119, Baltimore 21287
(410) 614-3853 (Phone)
Certifications:
Neurology, 1990
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Johns Hopkins Hospital Neurolgy
1800 Orleans St SUITE 119, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
1800 Orleans St SUITE 119, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Education:
Medical School
Case Western Reserve University School of Medicine
Graduated: 1984
University Of Michigan Hospitals
The Johns Hopkins Hospital
Case Western Reserve University School of Medicine
Graduated: 1984
University Of Michigan Hospitals
The Johns Hopkins Hospital
Immortalized Lines Of Endothelial Brain Cells And Therapeutic Applications Thereof
Immortalized Lines Of Endothelial Brain Cells And Therapeutic Applications Thereof
US Patent:
2004001, Jan 29, 2004
Filed:
May 19, 2003
Appl. No.:
10/440932
Inventors:
Nathalie Chaverot - Paris, FR
Pierre-Olivier Couraud - Auffargis, FR
John Laterra - Baltimore MD, US
Jerome Quinonero - Noisiel, FR
Francoise Roux - Paris, FR
Arthur Strosberg - Paris, FR
Jean-Leon Tchelingerian - Gif-Sur-Yvette, FR
Lionel Vignais - Paris, FR
Pierre-Olivier Couraud - Auffargis, FR
John Laterra - Baltimore MD, US
Jerome Quinonero - Noisiel, FR
Francoise Roux - Paris, FR
Arthur Strosberg - Paris, FR
Jean-Leon Tchelingerian - Gif-Sur-Yvette, FR
Lionel Vignais - Paris, FR
International Classification:
C12N005/08
US Classification:
435/368000
Abstract:
The invention relates to optionally modified immortalized lines of endothelial brain cells of mammalians, as well as applications as preventive or curative drug and particularly for the treatment of primary and secondary, neurologic or psychiatric diseases, including brain tumor, and for stimulating the growth and reproduction of breeding animals. The invention also relates to the method for preparing said cell lines. The endothelial cell lines of mammalians disclosed are comprised of immortalized endothelial brain cells presenting at least one of the following characteristics of differentiated endothelial brain cells, in a stable way: the expression of endothelial markers, the secretion of vasoactive substances, the expression of molecules of the major histocompatilility complex (MHC), the expression of hormonal receptors, and the existence of tight junctions; said cell lines comprise a nucleic acid fragment having at least one immortalizing fragment of a viral or cellular oncogene, optionally associated with at least one selection gene, and an expression vector comprising a sequence coding for polypeptide, a protein or a viral vector, optionally associated with at least one selection gene and optionally at least one marker gene, and they are capable in vivo to integrate brain vessels of a host mammalian and produce said polypeptide, said protein or said viral vector.
Combination Of Hgf Inhibitor And Hedgehog Inhibitor To Treat Cancer
Combination Of Hgf Inhibitor And Hedgehog Inhibitor To Treat Cancer
US Patent:
2011021, Sep 8, 2011
Filed:
Apr 9, 2009
Appl. No.:
12/935264
Inventors:
Daniel Fults - Holladay UT, US
John Laterra - Baltimore MD, US
Kyung Jin Kim - Cupertino CA, US
John Laterra - Baltimore MD, US
Kyung Jin Kim - Cupertino CA, US
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241331, 4241451, 4241421
Abstract:
The present invention is directed toward a method of treating cancer by administering to a patient an inhibitor of Hepatocyte Growth Factor and an inhibitor of the Hedgehog signaling pathway.
Brain Endothelial Cell Expression Patterns
Brain Endothelial Cell Expression Patterns
US Patent:
2010006, Mar 11, 2010
Filed:
Nov 11, 2009
Appl. No.:
12/616600
Inventors:
Stephen I. Madden - Sudbury MA, US
Clarence J. Wang - Arlington MA, US
Brian P. Cook - Northboro MA, US
John Laterra - Baltimore MD, US
Kevin Walter - Pittsburgh PA, US
Clarence J. Wang - Arlington MA, US
Brian P. Cook - Northboro MA, US
John Laterra - Baltimore MD, US
Kevin Walter - Pittsburgh PA, US
Assignee:
Genzyme Corporation - Framingham MA
International Classification:
A61K 39/395, C12Q 1/68, C40B 30/04, A61K 39/00, A61P 35/00
US Classification:
4241741, 435 6, 506 9, 4241841
Abstract:
To gain a better understanding of brain tumor angiogenesis, new techniques for isolating brain endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from brain ECS derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed genes that were specifically elevated in tumor-associated brain endothelium. These results confirm that neoplastic and normal endothelium in human brains are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
Combination Of Hgf Inhibitor And Egf Inhibitor To Treat Cancer
Combination Of Hgf Inhibitor And Egf Inhibitor To Treat Cancer
US Patent:
2009025, Oct 15, 2009
Filed:
Apr 9, 2009
Appl. No.:
12/421556
Inventors:
John Laterra - Baltimore MD, US
Bachchu Lal - Pikesville MD, US
Kyung Jin Kim - Cupertino CA, US
Bachchu Lal - Pikesville MD, US
Kyung Jin Kim - Cupertino CA, US
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241331, 4241411, 4241421
Abstract:
The present invention is directed toward a method of treating cancer by administering to a patient an inhibitor of Hepatocyte Growth Factor and an inhibitor of, e.g., Epidermal Growth Factor.
Combination Of Hgf Inhibitor And Egf Inhibitor To Treat Cancer
Combination Of Hgf Inhibitor And Egf Inhibitor To Treat Cancer
US Patent:
2012007, Mar 29, 2012
Filed:
Dec 8, 2010
Appl. No.:
12/963595
Inventors:
John Laterra - Baltimore MD, US
Bachchu Lal - Pikesville MD, US
Kyung Jin Kim - Cupertino CA, US
Bachchu Lal - Pikesville MD, US
Kyung Jin Kim - Cupertino CA, US
International Classification:
A61K 39/395, A61K 31/5377, A61K 31/517, A61P 35/00
US Classification:
4241331, 4241421, 5142345, 5142664
Abstract:
The present invention is directed toward a method of treating cancer by administering to a patient an inhibitor of Hepatocyte Growth Factor and an inhibitor of, e.g., Epidermal Growth Factor.
Brain Endothelial Cell Expression Patterns
Brain Endothelial Cell Expression Patterns
US Patent:
2012030, Dec 6, 2012
Filed:
Jul 9, 2012
Appl. No.:
13/544631
Inventors:
Stephen MADDEN - Sudbury MA, US
Clarence WANG - Arlington MA, US
Brian P. COOK - Northboro MA, US
John LATERRA - Baltimore MD, US
Kevin WALTER - , US
Clarence WANG - Arlington MA, US
Brian P. COOK - Northboro MA, US
John LATERRA - Baltimore MD, US
Kevin WALTER - , US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
GENZYME CORPORATION - Framingham MA
GENZYME CORPORATION - Framingham MA
International Classification:
C40B 30/04, C12Q 1/68, A61K 39/395, A61K 31/7088, A61K 51/10, A61K 39/00, A61P 37/04, G01N 33/574, A61P 35/00
US Classification:
424 149, 506 9, 435 723, 435 611, 435 612, 435 74, 435 71, 435 613, 435 619, 4241741, 4241581, 4241781, 4242771
Abstract:
To gain a better understanding of brain tumor angiogenesis, new techniques for isolating brain endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from brain ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed genes that were specifically elevated in tumor-associated brain endothelium. These results confirm that neoplastic and normal endothelium in human brains are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
Brain Endothelial Cell Expression Patterns
Brain Endothelial Cell Expression Patterns
US Patent:
2006012, Jun 15, 2006
Filed:
Aug 15, 2003
Appl. No.:
10/524432
Inventors:
Stephen Madden - Sudbury MA, US
Clarence Cook - Northboro MA, US
Brian Cook - Northboro MA, US
John Laterra - Baltimore MD, US
Kevin Walter - Pittsburgh PA, US
Clarence Cook - Northboro MA, US
Brian Cook - Northboro MA, US
John Laterra - Baltimore MD, US
Kevin Walter - Pittsburgh PA, US
Assignee:
Genzyme Corporation - Framingham
The John Hopkins University - Baltimore MD
The John Hopkins University - Baltimore MD
International Classification:
C12Q 1/68, G01N 33/567, G01N 33/53
US Classification:
435006000, 435007200
Abstract:
To gain a better understanding of brain tumor angiogenesis, new techniques for isolating brain endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from brain ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed genes that were specifically elevated in tumor-associated brain endothelium. These results confirm that neoplastic and normal endothelium in human brains are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
Methods Of Treating Brain Tumors With Antibodies
Methods Of Treating Brain Tumors With Antibodies
US Patent:
2010022, Sep 2, 2010
Filed:
Jan 19, 2010
Appl. No.:
12/690045
Inventors:
Kyung Jin Kim - Cupertino CA, US
John Laterra - Baltimore MD, US
Bachchu Lal - Pikesville MD, US
John Laterra - Baltimore MD, US
Bachchu Lal - Pikesville MD, US
Assignee:
Galaxy Biotech, LLC - Cupertino CA
Kennedy Krieger Institute, Inc. - Baltimore MD
Johns Hopkins University - Baltimore MD
Kennedy Krieger Institute, Inc. - Baltimore MD
Johns Hopkins University - Baltimore MD
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241331, 4241411, 4241451
Abstract:
The application is directed toward a method of treating a brain tumor in a patient comprising systemically administering a monoclonal antibody.
Methods Of Treating Brain Tumors With Antibodies
Methods Of Treating Brain Tumors With Antibodies
US Patent:
2007003, Feb 15, 2007
Filed:
Jun 1, 2006
Appl. No.:
11/446045
Inventors:
Kyung Kim - Cupertino CA, US
John Laterra - Baltimore MD, US
Bachchu Lal - Pikesville MD, US
John Laterra - Baltimore MD, US
Bachchu Lal - Pikesville MD, US
Assignee:
Galaxy Biotech, LLC - Cupertino CA
Kennedy Krieger Institute, Inc. - Baltimore MD
Johns Hopkins University - Baltimore MD
Kennedy Krieger Institute, Inc. - Baltimore MD
Johns Hopkins University - Baltimore MD
International Classification:
A61K 39/395, A61N 5/00
US Classification:
424155100, 600001000
Abstract:
The application is directed toward a method of treating a brain tumor in a patient comprising systemically administering a monoclonal antibody.